Immunomedics was a

biotechnology Biotechnology is the integration of natural sciences and engineering sciences in order to achieve the application of organisms, cells, parts thereof and molecular analogues for products and services. The term ''biotechnology'' was first used b ...

company focused on the development of

antibody-drug conjugate Antibody-drug conjugates or ADCs are a class of biopharmaceutical drugs designed as a targeted therapy for treating cancer. Unlike chemotherapy, ADCs are intended to target and kill tumor cells while sparing healthy cells. As of 2019, some 56 phar ...

s for the treatment of

cancer Cancer is a group of diseases involving abnormal cell growth with the potential to invade or spread to other parts of the body. These contrast with benign tumors, which do not spread. Possible signs and symptoms include a lump, abnormal b ...

. In 2020, the company was acquired by

Gilead Sciences Gilead Sciences, Inc. () is an American biopharmaceutical company headquartered in Foster City, California, that focuses on researching and developing antiviral drugs used in the treatment of HIV/AIDS, hepatitis B, hepatitis C, influenza, and CO ...

History

Immunomedics was founded in July 1982 by David M. Goldenberg. Michael Pehl was named CEO in December 2017 but left due to personal reasons in February 2019. At that time, Dr. Behzad Aghazadeh was named Executive Chairman. In October 2020,

acquired the company. In March 2022, Gilead announced the closing of the former Immunomedics facility in Morris Plains.

Products

Epratuzumab Epratuzumab (planned trade name LymphoCide) is a humanized monoclonal antibody. Potential uses may be found in oncology and in treatment of inflammatory autoimmune disorders, such as systemic lupus erythematosus (SLE). Clinical trials A clinic ...

is a humanized anti-CD22 monoclonal antibody in phase III trials for pediatric leukemia. *

Sacituzumab govitecan Sacituzumab govitecan, sold under the brand name Trodelvy, is a Trop-2-directed antibody and topoisomerase inhibitor drug conjugate used for the treatment of metastatic triple-negative breast cancer and metastatic urothelial cancer. The most co ...

(IMMU-132 / Trodelvy) is an anti-Trop-2-SN-38

for breast cancer and solid tumors. It was approved in April 2020 by the

FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ...

for the treatment of adult patients with metastatic triple-negative

breast cancer Breast cancer is cancer that develops from breast tissue. Signs of breast cancer may include a lump in the breast, a change in breast shape, dimpling of the skin, milk rejection, fluid coming from the nipple, a newly inverted nipple, or a re ...

(mTNBC) who have received at least two prior therapies for patients with relapsed or refractory

metastatic disease Metastasis is a pathogenic agent's spread from an initial or primary site to a different or secondary site within the host's body; the term is typically used when referring to metastasis by a cancerous tumor. The newly pathological sites, then, ...

. In 2017, the company scrapped a licensing deal for the drug with

Seagen SeaGen was the world's first large scale commercial tidal stream generator. It was four times more powerful than any other tidal stream generator in the world at the time of installation. It was successfully decommissioned by SIMEC Atlant ...

that led to the resignation of founder David M. Goldenberg. *

Labetuzumab Labetuzumab (marketed under the trade name CEA-CIDE) is a humanized IgG1 monoclonal antibody for the treatment of colorectal cancer. It selectively binds to carcinoembryonic cell adhesion molecule 5. Also tried in patients with MTC (medullary t ...

(IMMU-130) is an anti-CEACAM5-SN-38 antibody-drug conjugate in clinical trials for

colorectal cancer Colorectal cancer (CRC), also known as bowel cancer, colon cancer, or rectal cancer, is the development of cancer from the colon or rectum (parts of the large intestine). Signs and symptoms may include blood in the stool, a change in bowel m ...

. *

Veltuzumab Veltuzumab is a monoclonal antibody (targeted at CD20) which is being investigated for the treatment of non-Hodgkin's lymphoma. , it is undergoing Phase I/II clinical trials. When used with milatuzumab it showed activity. This drug was developed ...

is an anti-CD20 monoclonal antibody for treatment of cancer. *

Milatuzumab Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and is ...

(

IMMU-110 Milatuzumab (or hLL1) is an anti-CD74 humanized monoclonal antibody for the treatment of multiple myeloma non-Hodgkin's lymphoma and chronic lymphocytic leukemia. The drug is the first anti-CD74 antibody that has entered into human testing and i ...

) is an anti-CD74 monoclonal antibody for autoimmune diseases. * IMMU-114 is an anti-HLA-DR for hematological cancers.

References

{{authority control 1982 establishments in New Jersey 2020 mergers and acquisitions American companies established in 1982 Biotechnology companies established in 1982 Companies formerly listed on the Nasdaq Pharmaceutical companies established in 1982 Gilead Sciences Pharmaceutical companies of the United States Biotechnology companies of the United States Morris Plains, New Jersey Companies based in Morris County, New Jersey Biopharmaceutical companies Pharmaceutical companies based in New Jersey